Literature DB >> 8053176

Prevalence of HTLV types I and II among drug users in King County, Washington.

H Thiede1, N V Harris, J P McGough, B Roberts, R F Khabbaz, J E Kaplan.   

Abstract

We investigated the prevalence of human T-cell lymphotropic virus (HTLV) types I and II among drug users entering treatment in King County, Washington, between 1988 and 1990. Of 762 injection-drug users, 81 (10.6%) were HTLV-positive; of 89 noninjection-drug users, 2 (2%) were HTLV-positive. Most (95.8%) of those typed) were HTLV-II-positive. The relationship between HTLV and demographic and behavioral characteristics was further evaluated among injection-drug users. The prevalence rates for HTLV increased 25-fold from the youngest age group (15 to 24 years) to the oldest (older than 45 years), after adjusting for race. After adjustment for age, American Indians or Alaska Natives were 7.9 times, blacks 6.2 times, Asians or Pacific Islanders 4.7 times, and Hispanics 4.1 times as likely as whites to be HTLV-positive. The prevalence of HTLV among heroin injectors was more than double that observed among injectors of other drugs after adjusting for age, although this association was only marginally significant. The strong association between HTLV prevalence and age suggests that HTLV-II (the predominant virus) has been endemic among King County injection-drug users for some time. Its relatively high prevalence indicates that there is both an opportunity and a need to further investigate the epidemiologic and clinical implications of HTLV-II infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8053176      PMCID: PMC1022556     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  27 in total

1.  Sexual transmission of human T-lymphotropic virus type I (HTLV-I).

Authors:  E L Murphy; J P Figueroa; W N Gibbs; A Brathwaite; M Holding-Cobham; D Waters; B Cranston; B Hanchard; W A Blattner
Journal:  Ann Intern Med       Date:  1989-10-01       Impact factor: 25.391

2.  Transmission of retroviruses by transfusion of screened blood in patients undergoing cardiac surgery.

Authors:  N D Cohen; A Muñoz; B A Reitz; P K Ness; O H Frazier; D H Yawn; H Lee; W Blattner; J G Donahue; K E Nelson
Journal:  N Engl J Med       Date:  1989-05-04       Impact factor: 91.245

3.  Antibody to human retroviruses among drug users in three east coast American cities, 1972-1976.

Authors:  R J Biggar; Z Buskell-Bales; P N Yakshe; D Caussy; G Gridley; L Seeff
Journal:  J Infect Dis       Date:  1991-01       Impact factor: 5.226

4.  HTLV-II infection in Florida Indians.

Authors:  P H Levine; S Jacobson; R Elliott; A Cavallero; G Colclough; C Dorry; C Stephenson; R M Knigge; J Drummond; M Nishimura
Journal:  AIDS Res Hum Retroviruses       Date:  1993-02       Impact factor: 2.205

5.  Human T cell lymphotropic virus infection in Guaymi Indians from Panama.

Authors:  W C Reeves; J R Cutler; F Gracia; J E Kaplan; L Castillo; T M Hartley; M M Brenes; M Larreategui; S Loo de Lao; C Archbold
Journal:  Am J Trop Med Hyg       Date:  1990-10       Impact factor: 2.345

6.  Prevalence of antibodies to HTLV-I, -II, and -III in intravenous drug abusers from an AIDS endemic region.

Authors:  M Robert-Guroff; S H Weiss; J A Giron; A M Jennings; H M Ginzburg; I B Margolis; W A Blattner; R C Gallo
Journal:  JAMA       Date:  1986-06-13       Impact factor: 56.272

7.  Synthetic peptide-based immunoassays for distinguishing between human T-cell lymphotropic virus type I and type II infections in seropositive individuals.

Authors:  R B Lal; W Heneine; D L Rudolph; W B Present; D Hofhienz; T M Hartley; R F Khabbaz; J E Kaplan
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

8.  Seroprevalence and risk factors for HTLV-I/II infection among female prostitutes in the United States.

Authors:  R F Khabbaz; W W Darrow; T M Hartley; J Witte; J B Cohen; J French; P S Gill; J Potterat; R K Sikes; R Reich
Journal:  JAMA       Date:  1990-01-05       Impact factor: 56.272

9.  High frequency of human T-cell leukemia-lymphoma virus type II infection in New Mexico blood donors: determination by sequence-specific oligonucleotide hybridization.

Authors:  B Hjelle; R Scalf; S Swenson
Journal:  Blood       Date:  1990-08-01       Impact factor: 22.113

10.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

View more
  5 in total

1.  Estimating the prevalence of injection drug use among black and white adults in large U.S. metropolitan areas over time (1992--2002): estimation methods and prevalence trends.

Authors:  Hannah L F Cooper; Joanne E Brady; Samuel R Friedman; Barbara Tempalski; Karla Gostnell; Peter L Flom
Journal:  J Urban Health       Date:  2008-08-16       Impact factor: 3.671

2.  Risk factors for HTLV-II infection in Peruvian men who have sex with men.

Authors:  Joseph R Zunt; Alberto M La Rosa; Jesús Peinado; Javier R Lama; Luis Suarez; Monica Pun; Cesar Cabezas; Jorge Sanchez
Journal:  Am J Trop Med Hyg       Date:  2006-05       Impact factor: 2.345

3.  HTLV-II infection in the Western United States.

Authors:  B Hjelle
Journal:  West J Med       Date:  1994-06

4.  Human T-lymphotropic virus type II seroprevalence among emergency department and clinic patients.

Authors:  D Agranoff; K Varney; H Khayam-Bashi; E L Murphy
Journal:  West J Med       Date:  1996-06

5.  HTLV-2 infection in injection drug users in King County, Washington.

Authors:  Joseph R Zunt; Ken Tapia; Hanne Thiede; Rong Lee; Holly Hagan
Journal:  Scand J Infect Dis       Date:  2006
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.